Lilly Projects 2024 Revenue Miss as Zepbound, Mounjaro Disappoint
The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, sent Eli Lilly’s shares cratering by as much as 8% Tuesday, even as the company forecasted robust 2025 revenue.
Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.
24/7 Wall St. on MSN22h
Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...
I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...
Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...
A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?
With its innovative features and the upcoming launch of a direct medication purchasing service, Gala is set to become the ...
The most negatively impacted sectors are frozen, refrigerated, general food and beverages. Circana found GLP-1 users’ monthly ...
As the weight-loss drugs become more popular, consumer habits are starting to reflect changing consumption behavior, ...
Attorney General Kwame Raoul is warning Illinois residents seeking GLP-1 medications – Ozempic, Wegovy, Mounjaro, Zepbound ...
Weight loss drugs are seen as an easy option for dropping the pounds, but they are also expensive, and can have nasty side ...
Zacks.com on MSN1d
LLY Stock Down on Lower-Than-Expected Sales Guidance for Q4LLY's shares slip more than 6% as it cuts outlook for 2024 sales. Preliminary fourth-quarter revenues fall short of estimates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback